The FDA approved the Novartis AG's Rydapt on April 28. The drug is targeted toward AML patients and the FDA lists it for $22,500 for an average 42-day treatment.
FDA Approves Rydapt For Treatment Of Acute Myeloid Leukemia In Adult Patients
Tech Times - 1 May 2017 12:34
The FDA approved the Novartis AG's Rydapt on April 28. The drug is targeted toward AML patients and the FDA lists it for $22,500 for an average 42-day treatment.
Share this Article
Recommended